Quick Answer
CytoDyn Inc. reported Operating Income Loss of $9.66 million for the year ending 2025.
- CytoDyn Inc. showed an increase of +153.5% in Operating Income Loss from 2024 to 2025.
- This data is from CytoDyn Inc.'s annual report (Form 10-K), filed with the SEC on July 25, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), CytoDyn Inc.'s Operating Income Loss has grown by 361.2%.
- Historical annual values: Fiscal year 2025: $9.66 million | Fiscal year 2024: -$18.06 million | Fiscal year 2023: -$40.58 million | Fiscal year 2022: -$145.40 million | Fiscal year 2021: -$104.60 million | Fiscal year 2020: -$74.65 million | Fiscal year 2019: -$55.85 million | Fiscal year 2018: -$45.92 million | Fiscal year 2017: -$27.33 million | Fiscal year 2016: -$21.18 million | Fiscal year 2015: -$19.60 million | Fiscal year 2014: -$8.11 million | Fiscal year 2013: -$7.99 million | Fiscal year 2012: -$7.46 million | Fiscal year 2011: -$3.70 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: